FHTX · Insider Trading
Foghorn Therapeutics Inc. Common Stock
Every open-market purchase and sale reported by FHTX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-25 | B Lynne Parshall | Director | A | +28,000 deriv. | — |
| 2026-06-25 | Stuart Duty | Director | A | +28,000 deriv. | — |
| 2026-06-25 | Ian F Smith | Director | A | +28,000 deriv. | — |
| 2026-06-25 | Scott Biller | Director | A | +28,000 deriv. | — |
| 2026-06-25 | Neil Gallagher | Director | A | +28,000 deriv. | — |
| 2026-06-25 | Douglas G. Cole | Director | A | +28,000 deriv. | — |
| 2026-06-25 | Thomas J. Lynch Jr. | Director | A | +28,000 deriv. | — |
| 2026-06-25 | Simba Gill | Director | A | +28,000 deriv. | — |
| 2026-06-25 | Michael Mendelsohn | Director | A | +28,000 deriv. | — |
| 2026-04-13 | Adrian Gottschalk | Chief Executive Officer | G | — | — |
| 2026-02-24 | Ryan D Maynard | Chief Financial Officer | A | +400,000 deriv. | — |
| 2026-02-06 | Adrian Gottschalk | Chief Executive Officer | A | +1,075,000 deriv. | — |
| 2026-02-02 | Carlos Costa | Chief People Officer | A | +230,000 deriv. | — |
| 2026-02-02 | Michael LaCascia | Chief Legal Officer | A | +295,000 deriv. | — |
| 2026-02-02 | Alfonso Quintas Cardama | Chief Medical Officer | A | +300,000 deriv. | — |
| 2026-02-02 | Steven F. Bellon | Chief Scientific Officer | A | +300,000 deriv. | — |
| 2026-02-02 | Anna Rivkin | Chief Business Officer | A | +165,000 deriv. | — |
| 2026-01-15 | Flagship Ventures Opportunities Fund I, L.P. | Director | A | +44,709,360 deriv. | — |
| 2025-06-17 | Douglas G. Cole | Director | A | +25,000 deriv. | — |
| 2025-06-17 | B Lynne Parshall | Director | A | +25,000 deriv. | — |
| 2025-06-17 | Thomas J. Lynch Jr. | Director | A | +25,000 deriv. | — |
| 2025-06-17 | Michael Mendelsohn | Director | A | +25,000 deriv. | — |
| 2025-06-17 | Simba Gill | Director | A | +25,000 deriv. | — |
| 2025-06-17 | Ian F Smith | Director | A | +25,000 deriv. | — |
| 2025-06-17 | Scott Biller | Director | A | +25,000 deriv. | — |
| 2025-05-02 | Neil Gallagher | Director | A | +50,000 deriv. | — |
| 2025-05-02 | Stuart Duty | Director | A | +50,000 deriv. | — |
| 2025-04-28 | Adrian Gottschalk | Chief Executive Officer | G | — | — |
| 2025-04-10 | Adrian Gottschalk | Chief Executive Officer | G | — | — |
| 2025-01-24 | Kristian Humer | Chief Financial Officer | A | +120,000 deriv. | — |
| 2025-01-24 | Michael LaCascia | Chief Legal Officer | A | +126,000 deriv. | — |
| 2025-01-24 | Steven F. Bellon | Chief Scientific Officer | A | +140,000 deriv. | — |
| 2025-01-24 | Alfonso Quintas Cardama | Chief Medical Officer | A | +125,000 deriv. | — |
| 2025-01-24 | Carlos Costa | Chief People Officer | A | +115,000 deriv. | — |
| 2025-01-24 | Anna Rivkin | Chief Business Officer | A | +50,000 deriv. | — |
| 2025-01-24 | Adrian Gottschalk | Chief Executive Officer | A | +400,000 deriv. | — |
| 2024-09-24 | Carlos Costa | Chief People Officer | MIXED | — | −$231.51K |
| 2024-09-20 | Carlos Costa | Chief People Officer | MIXED | — | −$73.26K |
| 2024-09-18 | Carlos Costa | Chief People Officer | MIXED | — | −$67.43K |
| 2024-09-11 | Steven F. Bellon | Chief Scientific Officer | Sell | −20,000 | −$190.00K |
| 2024-09-04 | Anna Rivkin | Chief Business Officer | A | +190,000 deriv. | — |
| 2024-06-28 | B Lynne Parshall | Director | A | +16,000 deriv. | — |
| 2024-06-28 | Adam Koppel | Director | A | +16,000 deriv. | — |
| 2024-06-28 | Scott Biller | Director | A | +16,000 deriv. | — |
| 2024-06-28 | Thomas J. Lynch Jr. | Director | A | +16,000 deriv. | — |
| 2024-06-28 | Simba Gill | Director | A | +16,000 deriv. | — |
| 2024-06-28 | Michael Mendelsohn | Director | A | +16,000 deriv. | — |
| 2024-06-28 | Ian F Smith | Director | A | +16,000 deriv. | — |
| 2024-06-28 | Douglas G. Cole | Director | A | +16,000 deriv. | — |
| 2024-06-24 | Fanny Cavalie | Chief Strategy/Bus Ops Officer | — | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Adrian Gottschalk | Chief Executive Officer | 240,792 | $493.62K |
| Steven F. Bellon | Chief Scientific Officer | 151,957 | $311.51K |
| Simba Gill | Director | 34,061 | $69.83K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the FHTX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.